See more : PT Berkah Beton Sadaya Tbk (BEBS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Vimian Group AB (publ) (VIMGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vimian Group AB (publ), a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- P.I.E. Industrial Berhad (7095.KL) Income Statement Analysis – Financial Results
- Ironbark Capital Limited (IBC.AX) Income Statement Analysis – Financial Results
- C WorldWide Stabile Aktier KL A (CWISAKTKLA.CO) Income Statement Analysis – Financial Results
- Array Technologies, Inc. (ARRY) Income Statement Analysis – Financial Results
- MINT BS (BUDBS.PA) Income Statement Analysis – Financial Results
Vimian Group AB (publ) (VIMGF)
About Vimian Group AB (publ)
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 331.73M | 281.31M | 173.35M | 137.75M | 24.53M | 8.10M |
| Cost of Revenue | 102.30M | 87.32M | 50.50M | 42.24M | 9.10M | 3.50M |
| Gross Profit | 229.43M | 193.99M | 122.85M | 95.52M | 15.43M | 4.60M |
| Gross Profit Ratio | 69.16% | 68.96% | 70.87% | 69.34% | 62.91% | 56.76% |
| Research & Development | 5.67M | 8.36M | 2.41M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 56.93M | 41.88M | 22.47M | 5.44M | 2.43M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 153.91M | 56.93M | 41.88M | 22.47M | 5.44M | 2.43M |
| Other Expenses | 28.57M | 91.83M | 55.25M | 57.60M | 8.84M | 2.39M |
| Operating Expenses | 188.16M | 148.76M | 97.13M | 80.07M | 14.28M | 4.82M |
| Cost & Expenses | 290.46M | 236.07M | 147.63M | 122.31M | 23.38M | 8.33M |
| Interest Income | 549.00K | 21.00K | 25.00K | 323.00K | 7.00K | 0.00 |
| Interest Expense | 19.26M | 11.05M | 6.72M | 7.17M | 400.00K | 214.00K |
| Depreciation & Amortization | 25.88M | 27.23M | 16.69M | 7.03M | 2.80M | 678.00K |
| EBITDA | 69.19M | 66.32M | 40.98M | 65.16M | 4.06M | -83.00K |
| EBITDA Ratio | 20.86% | 23.57% | 23.64% | 59.41% | 16.54% | 9.72% |
| Operating Income | 41.27M | 39.36M | 21.60M | 74.80M | 1.26M | -1.07M |
| Operating Income Ratio | 12.44% | 13.99% | 12.46% | 54.30% | 5.15% | -13.24% |
| Total Other Income/Expenses | -21.82M | -38.44M | -8.84M | 53.80M | -536.00K | 98.00K |
| Income Before Tax | 19.45M | 924.00K | 12.76M | 59.71M | -1.07M | -975.00K |
| Income Before Tax Ratio | 5.86% | 0.33% | 7.36% | 43.34% | -4.36% | -12.03% |
| Income Tax Expense | 8.96M | 8.12M | 5.00M | 6.26M | 158.00K | -185.00K |
| Net Income | 9.84M | -7.20M | 6.59M | 52.79M | -1.23M | -790.00K |
| Net Income Ratio | 2.97% | -2.56% | 3.80% | 38.33% | -5.00% | -9.75% |
| EPS | 0.02 | -0.02 | 0.02 | 2.13 | 0.00 | 0.00 |
| EPS Diluted | 0.02 | -0.02 | 0.02 | 2.13 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 492.02M | 403.11M | 349.95M | 24.82M | 389.14M | 389.14M |
| Weighted Avg Shares Out (Dil) | 453.50M | 403.11M | 349.98M | 24.82M | 389.14M | 389.14M |
Source: https://incomestatements.info
Category: Stock Reports